HEXA
Overview
HEXA (Hexosaminidase A) is a lysosomal hydrolase enzyme encoded by the HEXA gene located on chromosome 15q23-24. This enzyme is one of two major hexosaminidase isoforms in humans and plays a critical role in the catabolism of gangliosides and other glycosphingolipids within lysosomes. HEXA deficiency results in Tay-Sachs disease, a devastating lysosomal storage disorder characterized by progressive neurodegeneration, developmental regression, and early death. The enzyme was first identified in the 1960s when researchers discovered that Tay-Sachs patients lacked measurable hexosaminidase A activity, establishing the molecular basis of this genetic disease.
Function/Biology
HEXA is a β-hexosaminidase isoform composed of two subunits: an α-subunit (encoded by HEXA) and a β-subunit (encoded by HEXB). The functional HEXA enzyme consists of an α-β heterodimer that catalyzes the hydrolytic cleavage of terminal N-acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc) residues from gangliosides and other glycoconjugates. This enzymatic activity is essential for the degradation of GM1 and GM2 gangliosides, which accumulate in neural tissue during development and throughout life.
...HEXA
Overview
HEXA (Hexosaminidase A) is a lysosomal hydrolase enzyme encoded by the HEXA gene located on chromosome 15q23-24. This enzyme is one of two major hexosaminidase isoforms in humans and plays a critical role in the catabolism of gangliosides and other glycosphingolipids within lysosomes. HEXA deficiency results in Tay-Sachs disease, a devastating lysosomal storage disorder characterized by progressive neurodegeneration, developmental regression, and early death. The enzyme was first identified in the 1960s when researchers discovered that Tay-Sachs patients lacked measurable hexosaminidase A activity, establishing the molecular basis of this genetic disease.
Function/Biology
HEXA is a β-hexosaminidase isoform composed of two subunits: an α-subunit (encoded by HEXA) and a β-subunit (encoded by HEXB). The functional HEXA enzyme consists of an α-β heterodimer that catalyzes the hydrolytic cleavage of terminal N-acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc) residues from gangliosides and other glycoconjugates. This enzymatic activity is essential for the degradation of GM1 and GM2 gangliosides, which accumulate in neural tissue during development and throughout life.
In healthy individuals, HEXA localizes to lysosomes through a mannose-6-phosphate targeting signal that directs the enzyme to acidic compartments where it functions optimally. The enzyme requires an acidic pH (typically 4.5-5.0) for maximal activity and contains multiple disulfide bonds that stabilize its three-dimensional structure. Beyond hexosaminidase function, the α-subunit participates in the formation of active enzyme complexes with the β-subunit, enabling substrate specificity and catalytic efficiency.
Role in Neurodegeneration
HEXA deficiency leads to the progressive accumulation of undegraded GM2 gangliosides and related lipids primarily in neurons, where these lipids are most abundant. In Tay-Sachs disease (infantile-onset), rapid accumulation of GM2 gangliosides in the central nervous system triggers widespread neuronal dysfunction, characterized by developmental regression beginning around 6 months of age, seizures, blindness due to retinal degeneration, and progressive loss of motor control. Death typically occurs by age 4-5 years.
Late-onset forms of HEXA deficiency (juvenile and adult variants) present with more gradual progression, including progressive motor neuron disease resembling amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and cognitive decline. The accumulation of lipids within neurons impairs lysosomal function, triggers oxidative stress, activates neuroinflammatory pathways, and ultimately leads to neuronal apoptosis. Secondary accumulation of other lipids and proteins compounds cellular toxicity, creating a cascade of neurodegenerative mechanisms.
Molecular Mechanisms
More than 100 pathogenic mutations in the HEXA gene have been identified, including missense mutations, nonsense mutations, deletions, and splice site variants. Mutations may reduce enzyme expression, impair protein folding, destabilize the α-β subunit complex, or abolish catalytic activity. In infantile-onset disease, most individuals are compound heterozygotes carrying two deleterious alleles.
At the cellular level, GM2 ganglioside accumulation within lysosomes overwhelms autophagy capacity, triggers endoplasmic reticulum stress through unfolded protein responses, and activates innate immune pathways including toll-like receptors. Accumulated lipids alter membrane composition and trafficking, disrupt mitochondrial function, and increase production of reactive oxygen species. Neuroinflammation, driven partly by glial activation, contributes significantly to neuronal death.
Clinical/Research Significance
Tay-Sachs disease serves as a paradigmatic lysosomal storage disorder and has informed our understanding of neuronal lipid metabolism and lysosomal function. Population-based carrier screening programs, particularly among Ashkenazi Jewish populations where carrier frequency reaches 1 in 30, have substantially reduced disease incidence in high-risk communities.
Therapeutic research has explored enzyme replacement therapy, substrate reduction therapy, and chaperone-assisted protein folding approaches. Gene therapy strategies utilizing adeno-associated viral vectors are in development. Understanding HEXA deficiency has also provided insights into non-canonical neuroinflammatory mechanisms in neurodegeneration more broadly.
- HEXB: Encodes the β-subunit partner of HEXA; mutations cause Sandhoff disease
- GM2-ganglioside: Primary substrate accumulated in HEXA deficiency
- Lysosomal storage disorders: Broader category of inherited metabolic diseases
- Neuronal ceroid lipofuscinoses: Related lysosomal disorders with neurodegeneration
- Neuroinflammation in neurodegeneration: Common pathogenic mechanism across multiple disorders